UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 544

Sortiert nach

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

The Lancet (British edition), 2010-03, Vol.375 (9718), p.895-905

2010

Link zum Volltext

Verfügbarkeit prüfen

Cognitive Function in a Randomized Trial of Evolocumab

The New England journal of medicine, 2017-08, Vol.377 (7), p.633-643

2017

Link zum Volltext

Verfügbarkeit prüfen

Inflammatory and Cholesterol Risk in the FOURIER Trial

Circulation (New York, N.Y.), 2018-07, Vol.138 (2), p.131-140

2018

Link zum Volltext

Verfügbarkeit prüfen

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Circulation (New York, N.Y.), 2018-01, Vol.137 (4), p.338-350

2018

Link zum Volltext

Verfügbarkeit prüfen

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

The Lancet (British edition), 2017-06, Vol.389 (10088), p.2473-2481

2017

Link zum Volltext

Verfügbarkeit prüfen

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

Lancet neurology, 2010-05, Vol.9 (5), p.469-480

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial

Journal of the American College of Cardiology, 2019-06, Vol.73 (23), p.2961-2970

2019

Link zum Volltext

Verfügbarkeit prüfen

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

Circulation (New York, N.Y.), 2019-03, Vol.139 (12), p.1483-1492

2019

Link zum Volltext

Verfügbarkeit prüfen

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

The American heart journal, 2016-03, Vol.173, p.94-101

2016

Link zum Volltext

Verfügbarkeit prüfen

Nocebo affects after COVID-19 vaccination

The Lancet regional health. Europe, 2022-01, Vol.12, p.100273-100273, Article 100273

Sever, Professor Peter

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

The Lancet (British edition), 2017-10, Vol.390 (10106), p.1962-1971

2017

Link zum Volltext

Verfügbarkeit prüfen

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

The Lancet (British edition), 2015-11, Vol.386 (10008), p.2059-2068

2015

Link zum Volltext

Verfügbarkeit prüfen

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

Circulation (New York, N.Y.), 2018-08, Vol.138 (8), p.756-766

2018

Link zum Volltext

Verfügbarkeit prüfen

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

Circulation (New York, N.Y.), 2020-05, Vol.141 (20), p.1600-1607

2020

Link zum Volltext

Verfügbarkeit prüfen

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

The lancet oncology, 2011, Vol.12 (1), p.65-82

2011

Link zum Volltext

Verfügbarkeit prüfen

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Stroke (1970), 2020-05, Vol.51 (5), p.1546-1554

2020

Link zum Volltext

Verfügbarkeit prüfen

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

The lancet. Diabetes & endocrinology, 2017-12, Vol.5 (12), p.941-950

2017

Link zum Volltext

Verfügbarkeit prüfen

First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH-Pilot study

International journal of cardiology, 2013-01, Vol.162 (3), p.189-192

2013

Link zum Volltext

Verfügbarkeit prüfen

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial

Circulation (New York, N.Y.), 2020-02, Vol.141 (8), p.616-623

2020

Link zum Volltext

Verfügbarkeit prüfen

The importance of a valid assessment of salt intake in individuals and populations. A scientific statement of the British and Irish Hypertension Society

Journal of human hypertension, 2019-05, Vol.33 (5), p.345-348

2019

Link zum Volltext

Verfügbarkeit prüfen

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK

European heart journal, 2011-10, Vol.32 (20), p.2525-2532

2011

Link zum Volltext

Verfügbarkeit prüfen

Hypertension management 2011: optimal combination therapy

European heart journal, 2011-10, Vol.32 (20), p.2499-2506

2011

Link zum Volltext

Verfügbarkeit prüfen

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

The Lancet (British edition), 2005-09, Vol.366 (9489), p.895-906

2005

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 544

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(522)
Mit Volltextzugriff
(482)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(319)
Life Sciences & Biomedicine
(300)
Humans
(278)
Male
(167)
Female
(166)
Middle Aged
(142)
Cardiovascular System & Cardiology
(139)
Aged
(114)
Biological And Medical Sciences
(108)
Medical Sciences
(102)
Adult
(96)
Hypertension - Drug Therapy
(96)
Hypertension
(95)
Peripheral Vascular Disease
(85)
Blood Pressure
(75)
Cardiac & Cardiovascular Systems
(68)
Antihypertensive Agents - Therapeutic Use
(64)
Treatment Outcome
(62)
General & Internal Medicine
(59)
Medicine, General & Internal
(59)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

Cognitive Function in a Randomized Trial of Evolocumab

Inflammatory and Cholesterol Risk in the FOURIER Trial

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke

Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial

Interpretation of the evidence for the efficacy and safety of statin therapy

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

Nocebo affects after COVID-19 vaccination

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER

The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism

Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 168 participants from randomised trials

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial

First-in-man safety evaluation of renal denervation for chronic systolic heart failure: Primary outcome from REACH-Pilot study

Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial

Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjects　― A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial

The importance of a valid assessment of salt intake in individuals and populations. A scientific statement of the British and Irish Hypertension Society

The Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UK

Hypertension management 2011: optimal combination therapy

Suchergebnisse filtern